Treatment of relapsed and refractory multiple myeloma
Explore this paper's citation graph
Summary
Refractory myeloma indicates disease unresponsive to the most recent therapy administered, and the salvage approaches that are used in patients with refractory or relapsed disease include high- dose dexamethasone, high-dose chemotherapy with autotransplantation, allogeneic hematopoietic stem cell transplantation, thalidomide-based therapies, and novel/ investigational agents.
- Type
- review
- Published
- 2003-06-01
- Cited by
- 8
- References
- 15
- OpenAlex
- https://openalex.org/W2013651845
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:12446632
Keywords
Medicine, Thalidomide, Salvage therapy, Multiple myeloma, Refractory (planetary science)
References
- Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.
- High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial.
- Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma
- Novel Therapies in Multiple Myeloma
- Non-myeloablative allogeneic transplantation (‘microallograft’) for refractory myeloma after two preceding autografts: feasibility and efficacy in a patient with active aspergillosis
- Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma
- High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions.
- Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma.
- Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations.
- The role of radiotherapy
- Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.
- Antitumor activity of thalidomide in refractory multiple myeloma.
- Autologous stem cell transplantation for relapsed and primary refractory myeloma
- Graft-versus-myeloma
- Early myeloablative therapy for multiple myeloma.
Cited by
- Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma.
- Head and neck manifestations of myeloma in Nigerians.
- Lenalidomide in Myeloma
- How I treat elderly patients with myeloma.
- Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.
- PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells
- Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
- Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
- Second and Third Line Treatment Strategies in Multiple Myeloma: a Referral-Center Experience
Related papers
- Cyclosporine Broadens the Therapeutic Potential of Lenalidomide in Myeloid Malignancies
- Lenalidomide-induced severe hepatotoxicity.
- Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide
- Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database
- Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis.
- Lenalidomide: the emerging role of a novel targeted agent in malignancies.
- Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma
- [Action mechanism of lenalidomide in hematological malignancies - review].
- New Immunomodulatory Drugs in Myeloma
- Mechanism of action of lenalidomide in hematological malignancies